There are much effective medicine currently available for treating glaucoma. However, their clinical efficacy is limited by traditional delivery systems, resulting in poor bioavailability, poor patient adherence, and increased side effects. By topical eye drops, intraocular injection or subconjunctival injection, and surgical implants, drug delivery systems can realize the purpose of sustained-release in target tissue. Poly(DL-lactide-co-glycolide), liposome, chitosan and other sustained-release materials with biodegradation and biocompatibility are becoming research focus gradually. Drug delivery systems have the possibility to become irreplaceable carriers for glaucoma therapy medicine.